In non-transplant @entity1 mild @entity3562 is an independent risk factor for @entity455 . The aim of this study was to determine whether @entity3562 is associated with graft @entity455 . Fasting total plasma @entity1255 was assessed in 18 @entity1 with graft vasculopathy and 18 transplanted @entity1 without graft vasculopathy matched for age, sex and the time since transplant. All were on cyclosporin. Graft vasculopathy was defined at coronary angiography as stenoses > or = 25%, or @entity439 . We found that @entity3562 ( > or = 15 micromol/l) is common among transplanted heart recipients and significantly more frequent in the @entity1 with graft vasculopathy (17/18 versus 11/18). Accordingly, the mean @entity3563 was significantly higher in the group with graft vasculopathy (23.6+/-7.8 versus 16.9+/-7.1 micromol/l, P=0.01). The elevation of @entity1255 plasma levels in the heart transplant recipients has probably multiple causes. The main cause seems to be @entity177 . Additional causes could be @entity500 treatment or genetic polymorphisms. These results suggest that besides the immunological factors, @entity1255 can play an additional role in the pathogenesis of graft @entity455 .

Association of mild XXXX with cardiac graft vascular disease.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity455 :: ('MESH:D014652', 'Disease') :: ['vascular disease'] @entity500 :: ('MESH:D001379', 'Chemical') :: ['azathioprine'] @entity1255 :: ('MESH:D006710', 'Chemical') :: ['homocysteine'] @entity3563 :: ('MESH:C566403', 'Disease') :: ['homocysteinemia'] @entity177 :: ('MESH:D051437', 'Disease') :: ['renal failure'] @entity439 :: ('MESH:D000783', 'Disease') :: ['aneurysms'] @entity3562 :: ('MESH:D020138', 'Disease') :: ['hyperhomocysteinemia']
@entity3562 :: (MESH:D020138,Disease) :: ['hyperhomocysteinemia']
